Regeneron Pharmaceuticals, Inc. (REGN) Business Profile

What it does

Regeneron Pharmaceuticals is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Founded in 1988 and headquartered in Eastview, it is led by Chair, President and Chief Executive Officer Leonard S. Schleifer, M.D., Ph.D.

The company’s approved medicines address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, blood conditions, infectious diseases, and rare diseases. Its eye medicines EYLEA HD and EYLEA treat retinal diseases including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. Dupixent is used across allergic and inflammatory conditions including atopic dermatitis, asthma, chronic obstructive pulmonary disease, and eosinophilic esophagitis.

Its oncology medicine Libtayo is approved in several cancers, including non-small cell lung cancer, basal cell carcinoma, cutaneous squamous cell carcinoma, and cervical cancer. Other marketed medicines include Praluent for cardiovascular risk reduction and cholesterol conditions, Kevzara for inflammatory conditions, Evkeeza for homozygous familial hypercholesterolemia, and medicines for rare diseases and infections.

Regeneron also runs clinical programs intended to add new uses for marketed medicines and create new medicines. These programs include antibodies, multi-antibody therapies, bispecific antibodies, RNA-based therapies, gene-editing programs, and gene therapy. A medicine generally must complete preclinical testing, clinical trials, and review by relevant health authorities before it can be commercialized.

How it makes money

Regeneron earns product revenue when it sells medicines for which it records net product sales, generally when a customer receives or accepts the product. Net product sales reflect deductions such as rebates, chargebacks, discounts under government and other programs, and distribution-related fees.

The company records U.S. net sales of EYLEA HD and EYLEA, which are treatments for retinal diseases. Bayer records sales outside the United States for these medicines, while Regeneron records its share of the associated profit in collaboration revenue. Regeneron records global sales of Libtayo and pays Sanofi a royalty on those sales. It records U.S. Praluent sales, while Sanofi records sales outside the United States and pays Regeneron a royalty.

Collaboration revenue is a second major route to earnings. Sanofi records global net sales of Dupixent and Kevzara, and Regeneron records its share of profits from those sales as collaboration revenue. Collaboration arrangements can also generate royalties, sales-based milestone payments, manufacturing-cost reimbursements, and reimbursement for agreed research and development work.

For fiscal 2025, collaboration revenue was $7.3 billion and EYLEA revenue was $2.8 billion; it was reported on 19 October 2026 that U.S. EYLEA revenue in Q2 FY2026 was $412.0 million.

Revenue therefore comes both from medicines Regeneron sells directly and from contractual shares of profits, royalties, and other payments on medicines commercialized with collaborators. Demand can recur as approved medicines are used by patients over time, but the amount earned depends on sales volumes, pricing, rebates and discounts, payor coverage, manufacturing availability, and the terms of collaboration agreements.

Customers and how it sells

Regeneron sells marketed products for which it records net product sales in the United States to distributor customers, including distributors and specialty pharmacies. Those customers generally sell medicines onward to healthcare providers or, where applicable, other pharmacies. The company’s direct customers are therefore intermediaries in the route to patients rather than the patients receiving treatment.

Customer concentration is material. Customer A represented 50.0% of revenue in FY2025, and Customer B represented 27.0% of revenue in FY2025. The company also depends on third-party payors, including private healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, Medicare, and Medicaid, because coverage, reimbursement, and copay assistance affect product use and sales.

Its commercial footprint includes the United States, the European Union, and Japan for many marketed medicines. Collaboration arrangements divide commercialization responsibilities by geography. Bayer commercializes EYLEA HD and EYLEA outside the United States, while Regeneron records its share of profits from those sales. Sanofi records global sales of Dupixent and Kevzara. Regeneron is responsible for Praluent development and commercialization in the United States, while Sanofi is responsible outside the United States. For Evkeeza, Regeneron is responsible in the United States and Ultragenyx is responsible outside it.

Suppliers and costs

Regeneron manufactures products itself and relies on collaborators, suppliers, and other third parties for steps including manufacturing, filling, finishing, packaging, labeling, and distribution. Its supply chain includes limited internal and contracted manufacturing capacity.

Catalent Indiana, LLC, part of Novo Nordisk A/S, was the manufacturing filler in the EYLEA HD biologics license application. Following an FDA inspection, unresolved findings at the site were cited as the sole approvability issue in a complete response letter for the EYLEA HD pre-filled syringe application. The company subsequently submitted an application using a new manufacturer.

The cost structure includes substantial research and development spending for clinical programs, manufacturing costs, and commercialization costs for marketed products. Under collaboration agreements, Regeneron may reimburse a collaborator for a share of research, development, or commercialization costs; it may also supply commercial product to a collaborator and receive manufacturing-cost reimbursement. Research, clinical development, regulatory compliance, manufacturing controls, product quality monitoring, selling activities, and post-approval studies can all require continuing expenditure.

The company expects research and development activity and costs not reimbursed by collaborators to expand and require additional resources. It also expects substantial commercialization costs for marketed products.

Competitive position

Regeneron faces pharmaceutical and biotechnology competition in marketed medicines and clinical development. Competition for approved medicines depends on efficacy, safety, reliability, route and ease of administration, dosing frequency, availability, price, and intellectual property position.

In retinal disease, EYLEA HD and EYLEA compete with Vabysmo and Avastin from Genentech/Roche; Lucentis from Novartis AG and Genentech/Roche; Beovu from Novartis AG; and biosimilar aflibercept products including Pavblu from Amgen Inc., Afqlir from Sandoz, and Eiyzey from Sam Chun Dang. These competitors are listed across the United States, European Union, and Japan, depending on product and indication.

In allergic and inflammatory disease, Dupixent competes with products from Eli Lilly and Company, AbbVie, AstraZeneca, GlaxoSmithKline, Roche, Novartis, Pfizer, and others across indications including atopic dermatitis, asthma, nasal polyps, chronic obstructive pulmonary disease, and chronic spontaneous urticaria. In oncology, Libtayo competes with Keytruda from Merck & Co., Inc., Opdivo from Bristol-Myers Squibb, Tecentriq from Roche, Imfinzi from AstraZeneca, and other cancer medicines.

Our reading: Regeneron’s research, development, manufacturing, and commercial capabilities provide a moderate moat because the company operates across the medicine life cycle, but competitors use multiple drug-development technologies and compete in the same diseases. [item1; item1a]

Our reading: Collaboration arrangements with Sanofi and Bayer extend commercialization reach, but they also make part of the revenue base dependent on counterparties’ performance and continuing agreements. [item1; item1a]

Growth opportunities

Regeneron’s growth programs include expanding approved medicines into additional diseases, advancing new medicines through clinical development, and commercializing products with collaborators. It has approximately 45 product candidates in clinical development, including marketed products being studied in additional indications; most of these candidates were developed in its laboratories.

For EYLEA HD, the company expects an FDA decision on the U.S. pre-filled syringe application in the second quarter of 2026. Its development program also includes additional retinal-disease studies. Dupixent’s program includes pediatric asthma, chronic pruritus of unknown origin, lichen simplex chronicus, pediatric chronic spontaneous urticaria, allergic fungal rhinosinusitis, and further geographic approvals. Libtayo is being studied in settings including non-small cell lung cancer, cutaneous squamous cell carcinoma, melanoma, and hepatocellular carcinoma.

The pipeline also includes late-stage and earlier-stage programs in allergy, oncology, hematology, cardiometabolic disease, neurology, rare disease, and gene therapy. Examples include programs for paroxysmal nocturnal hemoglobinuria, transthyretin amyloidosis, fibrodysplasia ossificans progressiva, myasthenia gravis, obesity, thrombosis, hearing deficit due to otoferlin-gene variants, and geographic atrophy.

The company expects research and development expenses not reimbursed by collaborators to expand. It was reported on 23 October 2026 that annual revenue increased 4.60% over the last five years. Whether clinical candidates become new revenue sources depends on clinical results, regulatory approvals, manufacturing readiness, reimbursement, and successful commercialization.

Structural risks

• Dependence on key medicines. Regeneron is substantially dependent on EYLEA HD, EYLEA, and Dupixent. Sales can be affected by utilization, market acceptance, safety and efficacy, reimbursement, pricing, and competitors’ products.

• Biosimilars and wider competition. EYLEA faces branded and biosimilar competition, while Dupixent and Libtayo compete with medicines from other pharmaceutical companies. Competition can be based on price, dosing, administration, efficacy, safety, availability, and intellectual property.

• Clinical and regulatory uncertainty. Drug development and maintaining approval are costly, time-consuming, and highly uncertain. Clinical results may not be replicated or lead to approval, and regulators can require additional information, impose a clinical hold, issue a complete response letter, or restrict product use.

• Supply-chain and manufacturing reliance. The company relies on limited internal and contracted manufacturing and supply-chain capacity. Suppliers and other third parties must perform manufacturing, filling, finishing, packaging, labeling, and distribution; inspection findings at a manufacturing filler can delay an application.

• Collaboration dependence. Sanofi, Bayer, and other counterparties participate in development, manufacturing, commercialization, profit sharing, and royalty arrangements. Termination or breach of a collaboration could harm the ability to develop, manufacture, or commercialize certain medicines and candidates.

• Payor, pricing, and legal exposure. Coverage and reimbursement decisions by government and private payors can affect access and demand. Changes in drug-pricing laws and policies, product-liability claims, intellectual-property disputes, litigation, and government investigations can also affect operations.

Bottom line

Our reading

Our reading: Regeneron is an integrated medicines business whose earnings combine direct product sales with collaboration profits, royalties, and reimbursements, particularly through arrangements involving Sanofi and Bayer. [item1; item7]

Our reading: Its commercial base is concentrated in key medicines and customers, while its clinical pipeline spans many disease areas and requires ongoing research, regulatory, manufacturing, and commercialization spending. [item1; item1a; item7]

Our reading: Biosimilar and branded competition in retinal disease, reliance on external manufacturing capacity, and dependence on collaboration partners are central operating exposures. [item1; item1a]